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Abstract
Background Patients receiving therapeutic paralysis may
experience inadequate sedation due to intrinsic limitations
of behavioral sedation assessment. Bispectral index
(BISTM) provides an objective measure of sedation; how-
ever, the role of BISTM is not well defined in intensive care
unit (ICU) patients on neuromuscular blocking agents
(NMBA).
Objective The aim of this study was to delineate the
relationship between BISTM and level of sedation for crit-
ically ill patients during therapeutic paralysis.
Methods This was a retrospective observational study
conducted in ICU patients receiving continuous infusion
NMBA and BISTM monitoring. The primary endpoint was
the correlation of BISTM\60 during therapeutic paralysis
with a Richmond Agitation Sedation Score (RASS) of -4
to -5 (i.e., deep or unarousable sedation) at the time of
emergence from therapeutic paralysis.
Results Thirty-one patients were included in the analysis.
Three of these patients (9.6 %) were inadequately sedated
upon emergence from paralysis; that is, restless or agitated
(RASS ?1 to ?2). We did not observe a correlation
between BISTM and RASS upon emergence from paralysis
(r = 0.27, p = 0.14). The sensitivity of BISTM\60 in
predicting deep sedation (RASS -5 to -4) was 100 %
(95 % confidence interval [CI] 0–100) with a positive
predictive value of 35.7 %. The sensitivity and positive
predictive value of BISTM\60 in predicting light sedation
or deeper (RASS -5 to -2) was 92.9 % (95 %CI
83.3–100) and 92.9 %, respectively.
Conclusion These results suggest that 1 in 10 critically ill
patients receiving therapeutic paralysis may be inade-
quately sedated. BISTM monitoring may serve as a useful
adjunctive measure of sedation in critically ill patients
receiving therapeutic paralysis.
Key Points
Currently, there is no reliable method to measure
level of sedation in therapeutically paralyzed patients
in the intensive care unit (ICU).
We did not observe a correlation between bispectral
index during paralysis and Richmond Agitation
Sedation Score (RASS) upon emergence from
paralysis.
Despite efforts to provide adequate sedation, as
many as one in ten critically ill patients receiving
therapeutic paralysis may be inadequately sedated.
Bispectral index may be useful as an adjunct
measure of sedation in this clinical scenario.
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1 Introduction
The use of neuromuscular blocking agents (NMBA) in the
intensive care unit (ICU) is typically limited to salvage
therapies involving mechanical ventilation [1]. However,
the perspective and practice of therapeutic paralysis is
changing in response to a clinical trial that demonstrated
mortality benefit in patients with early, severe acute res-
piratory distress syndrome (ARDS) [2]. Currently, there is
no standard method or validated tool for managing sedation
to facilitate therapeutic paralysis in critically ill patients.
While vital signs may be a signal of pain or agitation, they
are unreliable indicators and should not be used in isolation
in the assessment of pain or agitation [3].This void in
clinical monitoring exposes patients to both unique and
putative complications of over- and under-sedation, such as
conscious paralysis, prolonged mechanical ventilation, and
psychological sequelae. Previous studies have focused on
ICU-acquired weakness as the chief safety concern [1, 2];
there are signals supporting the probability of inadequate
sedation with NMBA use in the ICU. A small observational
study conducted in a surgical ICU found that 36 % of
patients were able to recall events during therapeutic
paralysis [4]. Additionally, sustained periods of increased
alpha activity—signaling possible awareness—were
observed on electroencephalography (EEG) in a sleep
study of patients undergoing therapeutic paralysis, sug-
gesting possible awareness [5].
The Society of Critical Care Medicine’s Pain, Agitation
and Delirium Guidelines suggest that bispectral index
(BISTM) may be used to assess sedation in patients
receiving NMBAs; however, no specific recommendations
(e.g., BISTM target range) are provided for this patient
population [3]. The BISTM is an objective, non-invasive
measure of brain function derived from EEG data and
converted by mathematical algorithms into a continuous
numerical value ranging from 0 to 100, with 100 repre-
senting full awareness and 0 representing no brain activity.
It is more practical than a full EEG for monitoring sedation
in the ICU as it requires fewer electrodes and is much
simpler to interpret. BISTM monitoring is used in patients
undergoing general anesthesia to mitigate the risk of
awareness [6, 7]; however, the role of BISTM has not been
clearly defined in patients undergoing therapeutic paralysis
in the ICU. Studies show varying correlation between
BISTM and sedation scales in non-paralyzed ICU patients;
however, behavioral sedation scales are not valid in this
population due to patients’ inability to communicate or
move [8–16]. Moreover, there are indications that neuro-
muscular blockade alone may affect BIS [17].
The purpose of this study was to delineate the relationship
between patients’ BISTM and level of sedation for critically
ill patients during therapeutic paralysis. The primary end-
point was correlation of BISTM\60 upon emergence from
therapeutic paralysis with a Richmond Agitation Sedation
Score (RASS) of -4 to -5 (i.e., deep or unarousable seda-
tion). Secondary endpoints included sensitivity of
BISTM\60 while on NMBA therapy in predicting sedation
level (i.e., RASS -5 to -4 or RASS -5 to -2).
2 Methods
This was a retrospective observational study conducted at a
large academic medical center in patients 18 years of age
or older that concurrently received continuous NMBAs and
BISTM monitoring in the ICU. Patients were excluded if
they received NMBAs for management of intracranial
hypertension, were in a persistently obtunded state, or if
they did not have adequate documentation of BISTM and
RASS values. Patients were also excluded if there was a
reduction in sedative or analgesic medications between the
last recorded BISTM while on NMBAs and emergence from
paralysis, as this violated the assumption that the level of
sedation at these two points in time were comparable.
Conversely, patients with an increase in dose of continuous
sedative or analgesic medications between these two points
in time were included. This would increase the potential to
capture patients who had been under-sedated prior to dis-
continuing the NMBA.
The primary team managed therapeutic paralysis, seda-
tion, and analgesia for each patient. The primary team also
determined whether BISTM was monitored and whether
this was used for titration of sedation for each patient.
Sedation was routinely measured and documented with
RASS in all ICU patients. As RASS is an inappropriate
measure of the level of sedation in paralyzed patients,
sedative drug dosage was either kept at a fixed rate or
titrated using the BISTM device (Aspect Medical Systems
A-2000TM BIS Monitoring System model 185-0205,
Aspect Medical Systems, Inc. Natick, MA, USA).
BISTM\60 was typically targeted based upon suggested
manufacturer data from anesthesia literature where a
level\60 was associated with a probability of low recall
[6, 7, 18, 21].
In the absence of a direct means to measure behavior
during therapeutic paralysis, time of emergence from
paralysis after discontinuation of NMBAs was selected as
the surrogate observational point for assessment of sedation
(Fig. 1). This allowed behavioral assessment of the patient
using RASS when the paralytic effect had dissipated for
comparison with the preceding BISTM while receiving
NMBAs. Time of emergence from paralysis was defined as
the first time one of the following criteria were met after
discontinuation of neuromuscular blockade: return of four
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out of four twitches of the facial or radial nerve (train of
four, TOF 4/4), respiratory rate greater than the set venti-
lator rate, or nurse documentation of patient movement.
The RASS on emergence from paralysis was defined as the
RASS documented at this time or within 30 minutes after
emergence from paralysis. If patients did not meet any of
these criteria, then initial titration in sedative and/or anal-
gesic medication was used as a signal of emergence from
paralysis. Levels of sedation were defined by the criteria
specified in the RASS behavioral sedation assessment tool
(Fig. 2) [19]. Inadequate sedation upon emergence from
therapeutic paralysis was narrowly defined by the sedative
range from ‘sustained awakening to voice’ through ‘com-
bative’ (RASS -1 to ?4). Doses of sedative and analgesic
medications were not included in the analysis as this was
beyond the scope of this study.
2.1 Statistical Analysis
Demographic data included age, sex, date of NMBA ini-
tiation, primary service, and Sequential Organ Failure
Assessment (SOFA) score [20]. Independent variables
included the last BISTM documented prior to
discontinuation of NMBA and RASS at the time of
emergence from paralysis.
For a = 0.05, a sample size of at least 13 subjects would
provide 80 % power to detect a correlation of 0.7 or greater
and a sample size of at least 16 subjects would provide
80 % power to detect a specificity or sensitivity of
0.8 ± 0.2. To assess the relationship between BISTM and
RASS, the Pearson correlation coefficient was determined.
Linearity was validated using residual plots from the
regression model. The sensitivity and specificity of
BISTM\60 in predicting unarousable to deep levels of
sedation (RASS -5 to -4) upon emergence from paralysis
were calculated. In the absence of a well defined target
level of sedation during therapeutic paralysis, the sensi-
tivity and specificity of BISTM\60 in predicting light
sedation or deeper were also calculated.
3 Results
Four hundred thirty-seven patients were screened for
inclusion. The majority of excluded patients did not have
BISTM values charted (Fig. 3). There were 31 patients
Fig. 1 Study design timeline. This diagram represents the timeline
for patients receiving NMBA in the ICU also showing the temporal
relationship of key events and data points used in the study. BIS
Bispectral index, ICU intensive care unit, NMBA neuromuscular
blocking agent, RASS Richmond Agitation Sedation Scale
Fig. 2 Richmond Agitation
Sedation Scale (RASS) [19] and
Bispectral Index (BIS) range
[18]
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included in the study analysis. Demographic data are
summarized in Table 1. Over half the patients included
were admitted to the medical ICU service (58 %, 18/31)
and received NMBAs for management of ARDS (61.3 %,
19/31).
Ninety percent (28/31) of patients had a BISTM\60
during paralysis. The majority of patients (61.3 %, 19/31)
had a RASS upon emergence from paralysis reflecting
unarousable to deep levels of sedation (RASS -5 to -4,
Fig. 2). Three patients (9.6 %) were restless or agitated
(RASS ?1 to ?2) on emergence from paralysis.
Among patients with BISTM\60 during paralysis
(n = 28), 26 patients (92.9 %, 95 % confidence interval
[CI] 83.3–100) had a level of sedation ranging from
unarousable to light (RASS -5 to -2) upon emergence
from paralysis (Table 3). Eighteen patients (64 %, 95 % CI
46.5–82) with BISTM\60 were unarousable or deeply
sedated (RASS -5 or -4) upon emergence from paralysis
(Table 2). Ten patients in the study had discordant RASS
and BISTM values (RASS -3 to ?2 despite BISTM\60).
The observed correlation between BISTM during paral-
ysis and RASS upon emergence from paralysis was not
statistically significant (r = 0.27, p = 0.14, Fig. 4). No
indication of non-linearity was observed in the residual
diagnostics.
The sensitivity of BISTM\60 in predicting an
unarousable to deep level of sedation (RASS of -5 to -4)
on emergence from paralysis was 100 % (95 % CI 0–100)
with a positive predictive value of 35.7 % (Table 2).
The sensitivity and positive predictive value of
BISTM\60 in predicting an unarousable to light level of
sedation (RASS -5 to -2) on emergence from paralysis
was 92.9 % (95 % CI 83.3–100) and 92.9 %, respectively.
The specificity of BISTM[60 in predicting moderate
sedation or lighter (RASS -3 to ?4) on emergence from
paralysis was 23.1 % (95 % CI 17–46). The specificity of
BISTM C60 in predicting inadequate sedation (RASS -1 to
?4) upon emergence was 33.3 % (95 % CI 0–86.7)
(Table 3).
4 Discussion
Approximately 9 in 10 patients with BISTM\60 during
therapeutic paralysis were unarousable to lightly sedated
(RASS -5 to -1) upon emergence from paralysis. These
Fig. 3 Included and excluded patients. BIS Bispectral index, GCS
Glasgow Coma Scale, ICP intracranial pressure, NMBA neuromus-
cular blocking agent, RASS Richmond Agitation Sedation Scale
Table 1 Demographic data
Age [mean years, SD] 45.6 ± 16.1
Male [n (%)] 17 (54.8 %)
SOFA score [mean, SD] 10.3 ± 3.3
Primary service [n (%)]
Medical ICU 18 (58.1 %)
Trauma ICU 3 (9.7 %)
Burn ICU 8 (25.8 %)
Neurosurgical ICU 1 (3.2 %)
Cardiothoracic surgery ICU 1 (3.2 %)
No change in sedation/analgesia dosesa 17 (55 %)
Increase in sedation and/or analgesia dosesa 14 (45 %)
Sedative/analgesic received [n (%)]
Continuous propofol/midazolam and opioidb 23 (74.2 %)
Continuous propofol/midazolam only 5 (16.1 %)
Opioidb only 3 (9.7 %)
Indication for NMBA [n (%)]
ARDS 19 (61.3 %)
Facilitation of ECLS 2 (6.4 %)
Other respiratory 7 (22.6 %)
Other 3 (9.7 %)
How emergence from paralysis was defined [n (%)]
Nurse documentation of patient movement 18 (58.1 %)
Train-of-four 4/4 8 (25.8 %)
Otherc 5 (16.1 %)
ARDS acute respiratory distress syndrome, ECLS extracorporeal life
support, ICU intensive care unit, NMBA neuromuscular blocking
agent, SOFA Sequential Organ Failure Assessment
a Between the time the last bispectral index on NMBA was recorded
and emergence from paralysis
b Continuous intravenous opioid
c Respiratory rate greater than set ventilator rate or titration of
sedative/analgesic medications
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results suggest a potential role for BIS in critically ill
patients for whom therapeutic paralysis may otherwise
mask inadequate sedation. BISTM\60 was shown to be
highly sensitive for identifying patients with deeper levels
of sedation (RASS -5 to -2) and provides some reassur-
ance that these patients may experience less awareness
while paralyzed. Conversely, our study only observed three
patients with BISTM[60, limiting our ability to comment
on the ability of BISTM to identify inadequate sedation
reliably. Where applicable, this is reflected in the wide
confidence intervals and reflects our uncertainty of the
sensitivity and specificity of the total population based on
our observations in this study population. While we nar-
rowly defined inadequate sedation as RASS -1 to ?4, no
attempt was made to further define the optimal level of
sedation during therapeutic paralysis nor does this study
attempt to address the target BISTM range to mitigate over-
sedation.
There was a weak correlation observed between BIS
during paralysis and RASS upon emergence from paralysis
but statistical significance was not achieved as we were not
powered to detect such a small magnitude of correlation
(Fig. 4). The correlation observed in this study was weaker
than that found in most previously published studies con-
ducted in non-paralyzed ICU patients [13–16]. The likely
explanation is the difference in the ability of RASS and
BISTM to detect differences in level of sedation throughout
the entire spectrum of sedation and agitation. BISTM
quantifies levels of deep sedation and anesthesia, whereas
RASS is designated to differentiate levels of agitation. A
study conducted in 72 volunteers given varying doses of
propofol, midazolam, isoflurane, and alfentanil found the
relationship between the probability of recall or
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Fig. 4 BIS versus RASS scatter plot. Pearson correlation = 0.27
(p = 0.14)
Table 3 Sensitivity and specificity for light to deep sedation
RASS on emergence from paralysis
Unarousable to light sedation (RASS -5
to -2)
Drowsy to agitated (RASS -1 to
?2)
Last BIS on
NMBA
BIS\60a 26 2 Positive predictive
value = 92.9 %
BIS C60a 2 1 Negative predictive
value = 33.3 %
Sensitivity = 92.9 % (95 % CI
83.3–100)
Specificity = 33.3 % (95 % CI
0–86.7)
BIS Bispectral index, CI confidence interval, NMBA neuromuscular blocking agent, RASS Richmond Agitation Sedation Scale
a BIS\60 is considered consistent with general anesthesia or deep anesthesia per device manufacturer [18]
Table 2 Sensitivity and specificity for deep sedation
RASS on emergence from paralysis
Unarousable to deep sedation (RASS
-5 to -4)
Moderate sedation to agitation (RASS
-3 to ?2)
Last BIS on
NMBA
BIS\60a 18 10 Positive predictive
value = 35.7 %
BIS C60a 0 3 Negative predictive
value = 100 %
Sensitivity = 100 % (95 % CI 0–100) Specificity = 23.1 % (95 % CI 17–46)
BIS Bispectral index, CI confidence interval, NMBA neuromuscular blocking agent, RASS Richmond Agitation Sedation Scale
a BIS\60 is considered consistent with general anesthesia or deep anesthesia per device manufacturer [18]
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consciousness and BISTM to be sigmoidal across the entire
range of BISTM [21]. Thus, at lower BISTM values, which
were observed in the majority of this cohort, there does not
appear to be a strong correlation between BISTM and
behavioral measures of sedation.
The apparent discrepancy between sensitivity and
correlation results may be explained by fundamental dif-
ferences between the tests. Sensitivity examined the
probability of correspondence between ranges of BISTM
and RASS scores (e.g., BISTM\60 vs RASS -2 to -5)
whereas correlation tested the correspondence between
scores (e.g., BISTM 40 vs RASS -4) throughout the
range. Therefore, BISTM does not appear to be capable of
precisely predicting the level of sedation; however, in
clinical terms, the sensitivity of BISTM\60 for predicting
light to deep sedation (RASS -2 to -5) suggests a rea-
sonable initial goal and target for monitoring and sedation
titration.
These findings may also illustrate a limitation to BISTM
monitoring in critically ill patients. BISTM was initially
derived from multivariate statistical models based on data
from EEG and behavioral scales in subjects receiving
various hypnotic agents and anesthetic protocols [18, 22,
23]. However, the patient population used to derive BISTM
comprised healthy volunteers and surgical patients; thus,
cautious, skeptical extrapolation to the ICU patient is
necessary. Cerebral ischemia, hypoxemia, and sepsis are
factors that may cause diffuse cerebral slowing resulting in
lower BIS and RASS [22]. Patients with intracranial
hypertension or a persistently obtunded state were exclu-
ded to reduce the effects of neurologic injury on the find-
ings. Moreover, there is evidence that administration of
endotoxin in healthy volunteers (eliciting elevations in
body temperature, tumor necrosis factor-a, cortisol, and
interleukin-6) resulted in increased non-rapid-eye-move-
ment (delta) sleep and decreased wakefulness [24]. It is
highly plausible that a similar state of inflammation and
acute phase reactant release is present in the critically ill
patient. The implications of these effects on the relation-
ship between RASS and BISTM and the probability of
awareness or wakefulness in this patient population remain
unclear.
Nine patients in the study had discordant RASS and
BISTM values (RASS -3 to ?4 despite BISTM\60). Three
patients were unique for large burn wounds and for
receiving relatively low doses of sedative and analgesic
medications. The former factor may account for their fal-
sely depressed BISTM, while the latter factor likely
accounts for lighter levels of sedation on emergence from
paralysis. Another common finding was that four of these
nine patients had history of alcohol or drug abuse, which
may represent an unknown risk factor for BISTM and RASS
discordance.
Neuromuscular blockade may have also falsely depres-
sed the values observed for BIS as paralysis effectively
ablated electromyographic activity. This possibility was
reported in a small proportion of volunteers that were
paralyzed with rocuronium without sedation [17]. In order
to account for possible ‘interference,’ this study was
designed without presumption of a correlation or threshold
between any BIS value and any level of sedation. Fur-
thermore, pacemakers, heating blankets, and hypothermia
have been reported to cause false changes in BISTM [25].
The administration of opioids has also been demonstrated
to have no effect on BISTM, although concurrent use of
opioids with propofol has been shown to contribute greatly
to loss of consciousness [26–28]. Since BISTM technology
has been modified to incorporate new data on EEG
response and novel anesthetic drugs and drug combina-
tions, it is unknown whether these inaccuracies remain for
newer generations of BISTM [29]. The results of this study
highlight the potential effect of these and other practical
challenges.
There were a number of limitations to this study. Most
notably, it was an observational study design with a small
sample size, thus limiting the conclusions that may be
drawn from the results. Second, in the absence of a gold
standard for measuring level of sedation during therapeutic
paralysis, RASS at the time of emergence from paralysis
was utilized as a surrogate for level of sedation during
paralysis. While imperfect, RASS upon emergence pro-
vides a crude indicator of sedation, likelihood of recall, and
possibility of awareness. This study does not directly
address recall of paralysis; it would be logistically difficult
to conduct follow-up interviews given the high mortality
rate of the cohort. This study is also limited by the
heterogeneity in defining emergence from paralysis. The
decision not to rely solely on TOF alone was based on the
imprecision and inaccuracy of this tool in critically ill
patients; a prospective study design would likely necessi-
tate similar compromises [30]. Including patients that
received one-time or increasing dosages of sedatives or
analgesics after cessation of NMBAs may have biased the
results to suggest deeper levels of sedation on emergence
from paralysis than were actually present during paralysis.
However, none of the 15 patients with BISTM\60 during
paralysis and constant analgesic and sedative exposure
were inadequately sedated (RASS -1 to ?4) upon emer-
gence from paralysis. This finding suggests that the inclu-
sion criteria did not significantly impact the results. Lastly,
the cohort was a small subset (7.1 %) of all patients
receiving NMBAs in the ICU. It is possible that BIS
monitoring was ordered for patients that were considered
high risk by clinicians that were expressly sensitive to the
possibility of inadequate sedation. Therefore, these findings
may not be representative of the larger population.
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This study highlights the risk of inadequate sedation
during therapeutic paralysis. The results further suggest an
implied risk of awareness, even in a small cohort. The
recent re-emergence of therapeutic paralysis in the context
of relative unfamiliarity and infrequent use further
increases the probability of poor management. Strategies
that may mitigate risk of inadequate sedation include
ensuring target sedation prior to paralysis, periodic cessa-
tion of NMBAs, amendment of administration instructions
for concurrent sedative orders to avoid titration based on
behavioral sedation assessment tools, limiting duration of
paralysis, and educating staff. Moreover, future studies
utilizing NMBAs as an intervention may assess the risk of
inadequate sedation and/or recall of paralysis as a safety
endpoint.
There appears to be a disquieting discrepancy between
the extremely low rate of awareness achieved in the
operating room (0.24 %) [31] and the relatively high rate
(36 %) [4] observed in critically ill patients that required
therapeutic paralysis. Studies guiding the accurate detec-
tion and prevention of awareness during paralysis in the
ICU patient are severely lacking. Research in this area is
complicated by difficulty in measuring adequate levels of
sedation, intrinsic complexity in defining achievement of
sedation goals in the paralyzed patient, the high mortality
and morbidity in this patient population, and the relative
infrequency of continuous NMBA use. Prospective, ran-
domized trials are needed to assess the utility of BISTM for
ensuring adequate sedation and reducing recall in patients
receiving NMBA in the ICU. Future research may identify
risk factors for inadequate sedation or recall of paralysis,
risk factors associated with discordance between BISTM
and true level of sedation, and the cost effectiveness of
BISTM in this setting. At present, there is no well defined
sedation goal for patients receiving NMBAs in the ICU,
and the optimum level of sedation in this population
remains to be determined.
5 Conclusion
In this small, retrospective observational study we
observed that one in ten critically ill patients receiving
therapeutic paralysis may be inadequately sedated. In this
study, BISTM provided high sensitivity for unarousable to
light levels of sedation but our data was insufficient to
make meaningful conclusions about the ability of BISTM to
detect inadequate sedation.
It is likely that similar to other strategies of managing
sedation and analgesia in paralyzed patients, BISTM is
confounded by many factors and is not reliable enough be
used as the sole method to mitigate the risk of inadequate
sedation. However, BISTM monitoring may serve as a
useful adjunctive measure of sedation in patients receiving
therapeutic paralysis. Future studies are needed to validate
the utility and constraints of BISTM in this patient
population.
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